International Journal of Life Sciences, Biotechnology and Pharma Research Vol. 13, No. 7, July 2024 Online ISSN: 2250-3137
Print ISSN: 2977-0122

DOI: 10.69605/ijlbpr_13.7.2024.65

REVIEW ARTICLE

To study the advancement in innovative treatment strategies to mitigate neuroinflammation in cases of stroke

Meeshan Singhal[1], Dr. Manoj Kumar[2]

[1]Tutor, Department of Microbiology, Dr. Balasaheb Vikhe Patil Rural Medical College Loni, Maharashtra, India
[2]Professor, Department of Community Medicine, Rajshree Medical Research institute and Hospital Bareilly, Uttar Pradesh, India

Corresponding author
Meeshan Singhal
Tutor, Department of Microbiology, Dr. Balasaheb Vikhe Patil Rural Medical College Loni, Maharashtra, India

Received Date: 23 May, 2024 Accepted Date: 27 June, 2024

ABSTRACT

Background: Neuroinflammation is an essential element in the development of stroke and has a substantial impact on the subsequent damage to the brain. Directing attention on neuroinflammation has promise for the development of novel treatment approaches. Recent breakthroughs in comprehending the processes that cause neuroinflammation have opened up opportunities for new therapies. This review discusses many potential treatment strategies targeting neuroinflammation in stroke. Stem cells, namely mesenchymal stem cells (MSCs) and neural stem cells (NSCs), have shown potential in decreasing neuroinflammation and facilitating recovery after a stroke. Induced pluripotent stem cells (iPSCs) has the ability to transform into diverse types of nerve cells and have the capacity to replace impaired neurons and glial cells, hence reducing neuroinflammation. Nanoparticles may be designed to transport anti-inflammatory medications precisely to the location of damage, so improving the effectiveness of the pharmaceuticals and minimizing any adverse effects on the whole body. Liposomes, polymeric nanoparticles, and dendrimers are being investigated as potential nanoparticles for this specific objective. Gold nanoparticles possess anti-inflammatory characteristics and have the ability to traverse the blood-brain barrier. RNA interference (RNAi) technology may be used to suppress the activity of pro-inflammatory genes that play a role in the process of neuroinflammation. Preclinical models of stroke have shown the promise of siRNA and miRNA treatments. Monoclonal antibodies that specifically target inflammatory cytokines such as IL-1β and TNF-α have shown effectiveness in decreasing neuroinflammation. These antibodies have the ability to counteract the effects of pro-inflammatory cytokines by inhibiting their binding to receptors on target cells. Administering anti-inflammatory cytokines, such as IL-10 and TGF-β, may alter the immune response to become more anti-inflammatory, hence decreasing tissue damage and facilitating the healing process. The ongoing inquiry into novel therapeutic approaches for mitigating neuroinflammation in stroke has significant promise. Cellular therapies, drug delivery systems using nanoparticles, gene therapy, immunomodulatory medications, and natural substances provide several methods to selectively target and reduce neuroinflammation. Continual advancements in these areas, supported by rigorous clinical research, are crucial for effectively transitioning these therapies from experimental phases to practical use, ultimately improving outcomes for stroke patients.

INTRODUCTION

Stroke is a leading cause of death and long-term disability among illnesses in the USA [1]. In the United States, a stroke occurs every 40 seconds. Stroke is usually categorized into two main types: ischemic and hemorrhagic. Approximately 86% of strokes are caused by cerebral ischemia, which is the consequence of blood flow to the brain being blocked by a clot. This interruption leads to a lack of oxygen and nutrients in the brain, eventually causing primary brain damage [2]. Subsequently, the brain might experience a series of secondary damage cascades. Cellular energy depletion results in the disruption of intracellular homeostasis and the elevation of intracellular calcium levels, as well as the accumulation of neurotoxic amounts of dopamine and glutamate. This may also result in the dissipation of ion gradients due to the disruption of ATP-dependent ion channels, buildup of reactive oxygen species (ROS), malfunction of mitochondria, and excitotoxicity [3]. Brain edema, whether cellular or vasogenic, is a significant component that may exacerbate the outcome of a stroke due to an imbalance in cellular homeostasis and the breakdown

DOI: 10.69605/ijlbpr_13.7.2024.65

of the blood-brain barrier (BBB). The latter enhances the absorption of fluids into the brain tissue, resulting in an elevation of the intracranial pressure [4]. Ischemic stroke is a condition that involves both neuronal and vascular problems. Currently, r-tPA is the only medicine licensed by the US Food and medicine Administration (FDA) for treating acute ischemic stroke [5]. In recent times, endovascular mechanical thrombectomy has been used for the treatment of ischemic stroke in instances of major artery obstruction. Furthermore, neuroprotective treatments have been explored in ischemic stroke to enhance neuronal survival and improve the prognosis of the stroke [6]. The penumbra, which refers to the healthy tissue around the severely damaged and irreversible ischemic core, may be safeguarded by promptly administering suitable therapies after an injury. This is feasible due to the gradual death of cells in this region, allowing for the prevention of continued harm by targeted interventions.

Present stroke treatment methods and their constraints

Ischemic stroke has an intricate pathobiology that encompasses several routes and variables which contribute to brain damage caused by reduced blood flow at various stages after the ischemic event. Ischemic brain damage and neuronal cell death include many important pathways, including anoxic depolarization, disruption of the blood-brain barrier, excitotoxic cell death, oxidative stress, reactive astrogliosis, edema formation, white matter injury, and inflammation [3]. The current therapeutic methods for ischemic stroke mostly include either thrombolysis or neuroprotection. The primary objective of therapy for ischemic stroke is to promptly maintain the penumbra and halt the advancement of the ischemic core, therefore mitigating the negative neurological consequences. R-tPA is the only medicine authorized by the FDA for treating ischemic stroke. It is a thrombolytic agent that dissolves fibrin clots. Nevertheless, there have been several documented constraints regarding its use, including the need to promptly deliver it after the beginning of stroke in eligible patients who satisfy the clinical requirements. Additionally, it might lead to potentially severe negative consequences, such as hemorrhagic transformation and cellular damage after the restoration of cerebral blood flow [2]. tPA induces an increase in brain matrix metalloproteinases in cerebral endothelial cells. The heightened proteolytic activity of these enzymes exacerbates the outcome of a stroke by facilitating the development of edema, amplifying inflammatory signals, and breaking down BBB substrates [7]. In addition, ischemic stroke involves neuronal elements. The pathogenesis of ischemic stroke includes both primary and secondary brain damage, leading to neuronal destruction. Thus, in addition to enhanced canalization, there is a clear need for neuroprotective strategies that may rescue ischemic brain damage and enhance both short-term and long-term results of ischemic stroke. In recent times, endovascular therapy has progressed to become a conventional treatment for acute ischemic stroke, particularly in cases where there is occlusion of big blood arteries and the required results cannot be achieved with tPA. Endovascular therapy may enhance the opening of a blocked blood vessel, allowing for more accurate assessment of the efficacy of neuroprotective medications by targeted drug administration at the specific site of action.

Neuroinflammation is a crucial element in the development of stroke and has a substantial impact on the subsequent damage to the brain. Developing novel treatment techniques has the potential to be achieved by targeting neuroinflammation. Recent breakthroughs in comprehending the processes that cause neuroinflammation have opened up opportunities for new therapies.

Cell-Based Therapies for Alleviating Neuroinflammation in Stroke

Cell-based treatments have become viable methods for reducing neuroinflammation in stroke due to their ability to regulate immune responses, facilitate tissue regeneration, and improve neuroprotection. This study examines the several categories of cell-based treatments and their specific mechanisms of action in relation to stroke[8].

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) have important abilities to modulate the immune system, which are essential for decreasing neuroinflammation. They release anti-inflammatory cytokines, including as IL-10 and TGF-β, and prevent the activation of microglia and astrocytes. MSCs facilitate the restoration of injured tissue by means of paracrine signaling and direct cell replacement. Preclinical studies have shown that MSCs have the ability to decrease the extent of tissue damage caused by stroke, enhance neurological function, and lower the levels of pro-inflammatory cytokines in animal models. Current clinical studies are being conducted to assess the safety and effectiveness of MSCs in individuals who have suffered from strokes[9].

Neural Stem Cells (NSCs)

Neural stem cells (NSCs) has the capacity to undergo differentiation into neurons, astrocytes, and oligodendrocytes, hence aiding in the regeneration of impaired cells. In addition, they release neurotrophic factors that promote the survival of neurons and regulate the inflammatory environment by decreasing the activity of microglia that promote inflammation. Transplanting NSCs has shown potential in stroke animal models, resulting in enhanced functional results and decreased inflammation. Currently, clinical studies are in their first phases, investigating

DOI: 10.69605/ijlbpr_13.7.2024.65

the potential of neural stem cells (NSCs) in the treatment of strokes in humans[10].

Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells (iPSCs) have the ability to undergo differentiation into multiple types of brain cells, making them a valuable resource for cell replacement treatment. Cells produced from induced pluripotent stem cells (iPSCs) have the ability to regulate the immune response, facilitate the regeneration of tissues, and release substances that decrease neuroinflammation. Studies using neural cells produced from induced pluripotent stem cells (iPSCs) have shown promise in mitigating neuroinflammation and enhancing outcomes in models of stroke. Currently, preclinical and early-phase clinical studies are assessing the safety and effectiveness of medicines based on induced pluripotent stem cells (iPSCs).

Microglial Modulation

Microglia are the immune cells that permanently stay in the central nervous system and have a crucial function in neuroinflammation. Therapies targeting the modulation of microglial activity, such as the transplantation of genetically modified microglial cells or the use of drugs that affect microglial behavior, have the potential to decrease detrimental inflammation and promote the process of recovery. Research has shown that manipulating the activity of microglial cells using methods involving cells may decrease neuroinflammation and enhance the protection of neurons in animal models of stroke[11].

Cell-based therapeutics show great potential in addressing neuroinflammation in stroke, making them an attractive area of research. Mesenchymal stem cells, neural stem cells, induced pluripotent stem cells, and strategies focusing on microglial regulation provide many ways to decrease inflammation and facilitate healing. Ongoing research and clinical studies are crucial in order to fully harness the promise of these therapies and convert them into viable treatments for individuals suffering from stroke.

Nanoparticle-Based Therapies for Alleviating Neuroinflammation in Stroke

Nanoparticle-based therapeutics provide novel strategies for specifically addressing neuroinflammation in stroke. Nanoparticles has the ability to traverse the blood-brain barrier and administer therapeutic drugs precisely at the site of harm, owing to their diminutive size and customisable surface features. This section provides an overview of several kinds of nanoparticles and their actions in mitigating neuroinflammation in stroke.

Lipid-Based Nanoparticles

Lipid-based nanoparticles, such as liposomes and solid lipid nanoparticles, have the ability to encapsulate medications that are both hydrophilic and hydrophobic. This allows for targeted distribution and controlled release of the pharmaceuticals. These particles may be modified to transport anti-inflammatory medications, cytokines, or genetic material (such as siRNA) in order to regulate the immune response and decrease neuroinflammation. Studies have shown that lipid-based nanoparticles are successful in transporting anti-inflammatory substances to the brain. This leads to a decrease in the presence of pro-inflammatory cytokines and a reduction in neuronal harm in animal models of stroke[12].

Polymeric Nanoparticles

Polymeric nanoparticles, composed of substances like PLGA (poly(lactic-co-glycolic acid)), have the ability to provide continuous medication release and safeguard enclosed pharmaceuticals from deterioration. These particles may be modified with ligands that selectively bind to certain cells, so improving the accuracy of medication delivery to inflammatory areas of the brain. Research has shown that using polymeric nanoparticles with anti-inflammatory medicines or genes may decrease neuroinflammation, promote neuroprotection, and improve functional recovery in stroke models[13].

Gold Nanoparticles

Gold nanoparticles (AuNPs) possess distinctive optical and electrical characteristics that make them well-suited for therapeutic purposes. Anti-inflammatory drugs or antibodies that target inflammatory cytokines may be used to conjugate them, enabling precise regulation of the inflammatory response. Gold nanoparticles (AuNPs) have shown the ability to traverse the blood-brain barrier and inhibit the activation of microglia and astrocytes. This results in a reduction of neuroinflammation and better neurological outcomes in experimental stroke models[14].

Magnetic Nanoparticles

External magnetic fields may be used to direct magnetic nanoparticles, such as superparamagnetic iron oxide nanoparticles (SPIONs), to precise locations. They may be modified to transport anti-inflammatory medications or genes, offering targeted therapy to decrease neuroinflammation. Superparamagnetic iron oxide nanoparticles (SPIONs) have shown effectiveness in decreasing neuroinflammation and facilitating recuperation in stroke models, underscoring its promise for precise treatment in neuroinflammatoryconditions[15].

Cerium Oxide Nanoparticles

Cerium oxide nanoparticles (CeNPs) have antioxidant capabilities that enable them to eliminate reactive oxygen species (ROS) and alleviate oxidative stress, a significant cause of neuroinflammation in stroke. In

DOI: 10.69605/ijlbpr_13.7.2024.65

addition, they have the ability to regulate the activity of microglia and astrocytes, resulting in a further decrease in inflammation. CeNPs have shown the ability to mitigate oxidative stress, diminish neuroinflammation, and enhance functional results in stroke animal models[16].

Nanoparticle-based therapeutics show potential for mitigating neuroinflammation in stroke. Nanoparticles composed of lipids, polymers, gold, magnets, and cerium oxide have shown effectiveness in preclinical investigations, showcasing their ability to provide specific anti-inflammatory therapies. Further investigation and innovation are necessary to effectively use these discoveries in medical practice, providing renewed optimism for those suffering from strokes.

Gene Therapy for Alleviating Neuroinflammation in Stroke

Gene therapy is an advanced method for treating neuroinflammation in stroke. It focuses on particular biochemical pathways that are implicated in the inflammatory response. Gene therapy is a medical procedure that includes manipulating genes in a patient's cells to produce therapeutic outcomes, which might include introducing, removing, or modifying genes. In this article, we examine several gene therapy approaches and their potential for reducing neuroinflammation in stroke.

RNA Interference (RNAi)

RNA interference (RNAi) is a biological mechanism in which RNA molecules suppress gene expression by deactivating specific mRNA molecules. siRNA and miRNA may be used to suppress genes involved in the inflammatory response, therefore diminishing the synthesis of pro-inflammatory cytokines and mediators.

Research has shown that siRNA, which targets particular pro-inflammatory cytokines like TNF-α or IL-1β, may decrease neuroinflammation and enhance results in animal models of stroke[17].

CRISPR-Cas9 Gene Editing

The CRISPR-Cas9 technology enables accurate manipulation of the genome by creating targeted breaks at particular DNA sites. These breaks may subsequently be repaired to either disable or rectify genes associated with neuroinflammation. This method may be used to remove genes responsible for encoding pro-inflammatory cytokines or other substances that cause inflammation. CRISPR-Cas9 has been used in animal models to disrupt genes like TNF-α, leading to decreased neuroinflammation and enhanced neurological recovery after a stroke[18].

Gene Therapy Using Viral Vectors

Viral vectors, including adenoviruses, adeno-associated viruses (AAV), and lentiviruses, have the capability to transport genes that encode anti-inflammatory proteins or neuroprotective molecules to the brain. These vectors have the potential to give prolonged protection against neuroinflammation by providing long-term expression of therapeutic genes. Delivery of anti-inflammatory cytokines such as IL-10 via AAV has shown potential in decreasing neuroinflammation and facilitating recovery in stroke models[19].

Gene Therapy Targeting Endogenous Anti-Inflammatory Pathways

Augmenting the production of naturally occurring anti-inflammatory substances, such as IL-10, IL-4, and TGF-β, may assist in regulating the immune response. Gene therapy might be used to enhance the synthesis of these anti-inflammatory cytokines inside the brain, therefore diminishing neuroinflammation. Experimental stroke models have shown that gene therapy techniques that enhance the production of IL-10 or TGF-β lead to significant decreases in neuroinflammation and better neurological outcomes[20].

Targeted Delivery Systems for Gene Therapy

Targeted delivery technologies, such as nanoparticles and liposomes, improve the precision and effectiveness of gene therapy. These systems may be engineered to selectively transport genetic material to neurons, glial cells, or endothelial cells in the brain, reducing unintended consequences and optimizing therapeutic advantages. Nanoparticle-mediated delivery methods for gene therapy have shown enhanced effectiveness in transporting genetic material to the brain, leading to improved regulation of the inflammatory response and enhanced functional recovery in stroke models[21].

Gene therapy has the ability to effectively reduce neuroinflammation in stroke by specifically targeting the molecular pathways that are involved in the inflammatory response. RNA interference, CRISPR-Cas9 gene editing, viral vector delivery, and targeted delivery systems are effective techniques that show potential in reducing inflammation and enhancing neurological results. Continuing research and clinical trials are crucial in order to transform these hopeful methods into successful therapies for individuals suffering from stroke.

Immunomodulatory Agents for Alleviating Neuroinflammation in Stroke

Immunomodulatory drugs provide a hopeful therapeutic approach for reducing neuroinflammation in stroke. These medicines have the ability to regulate the immune response, decrease the generation of pro-inflammatory cytokines, and improve neuroprotective processes. In this study, we examine several categories of immunomodulatory drugs and their prospective use in the treatment of neuroinflammation in stroke.

DOI: 10.69605/ijlbpr_13.7.2024.65

Corticosteroids

Corticosteroids, such as dexamethasone and methylprednisolone, are powerful anti-inflammatory substances that suppress the immune response by blocking the synthesis of pro-inflammatory cytokines (such as TNF-α and IL-1β) and decreasing the activity of immune cells like microglia and astrocytes. Studies have shown that corticosteroids may decrease neuroinflammation and enhance results in animal models of stroke. Nevertheless, the use of these substances in clinical environments is restricted because of their possible adverse reactions and the possibility of immunosuppression[22].

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and aspirin, impede the activity of cyclooxygenase (COX) enzymes, which play a role in producing pro-inflammatory prostaglandins. NSAIDs may diminish inflammation and alleviate pain by lowering the synthesis of these mediators. Although NSAIDs are successful in decreasing inflammation in the peripheral areas, their effects on neuroinflammation in stroke are not well understood. While several studies have shown advantages, others have revealed restricted effectiveness and possible dangers of gastrointestinal and cardiovascular adverse effects[23].

Cytokine Inhibitors

Cytokine inhibitors selectively target pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. Some examples of these are monoclonal antibodies such as infliximab, which is an antibody that targets TNF-α, and receptor antagonists like anakinra, which is an antagonist of the IL-1 receptor. Cytokine inhibitors in animal stroke models have shown efficacy in reducing neuroinflammation, decreasing infarct size, and improving functional outcomes. Ongoing clinical studies are being conducted to assess the safety and effectiveness of these treatments in individuals with stroke[24].

Immunosuppressive Agents

Immunosuppressive drugs, such as cyclosporine and tacrolimus, hinder the activation and growth of immune cells. These medicines have the ability to decrease the total immune response, which includes reducing neuroinflammation, by specifically targeting the pathways that are involved in T-cell activation and cytokine generation. Cyclosporine and tacrolimus have shown neuroprotective properties in animal stroke models, principally via the reduction of neuroinflammation and apoptosis. Additional clinical trials are required to further investigate the potential of these treatments in stroke therapy[25].

Minocycline

Minocycline is a tetracycline antibiotic that has a wide range of effectiveness against different types of bacteria. It has also been shown to have qualities that reduce inflammation and protect the nervous system. It hinders the activation of microglia and decreases the production of pro-inflammatory cytokines and matrix metalloproteinases (MMPs). Studies have shown that Minocycline may effectively decrease neuroinflammation, reduce the size of infarcts, and enhance functional results in animal models of stroke. Clinical studies have shown inconclusive findings, suggesting some advantages but also emphasizing the need for more research[26].

Statins

Statins, which are often used for their cholesterol-reducing benefits, also have anti-inflammatory characteristics. They hinder the mevalonate pathway, resulting in decreased synthesis of substances that cause inflammation and increased production of substances that protect the nervous system. Studies have shown that statins may decrease neuroinflammation, stimulate the growth of new blood vessels, and enhance the restoration of normal function in animal models of stroke. Empirical research indicates that statins may enhance outcomes in individuals who have had a stroke, however the specific processes are still being studied[27]. Immunomodulatory drugs provide many approaches to decrease neuroinflammation in stroke. Corticosteroids, NSAIDs, cytokine inhibitors, immunosuppressive drugs, minocycline, and statins have shown different levels of effectiveness in both preclinical and clinical investigations. Ongoing research and clinical studies are necessary to determine the safety, effectiveness, and best practices for using these substances in treating neuroinflammation caused by stroke.

Gut Microbiota Modulation

Emerging evidence suggests a link between gut microbiota composition and stroke outcomes. Gut microbiota dysbiosis is associated with increased inflammation, which is a key component of stroke pathogenesis. Modulating the gut microbiota to restore a healthy balance can reduce inflammation and improve stroke outcomes [28]. Therapeutic interventionstargeting the gut-brain axis, such as probiotics, prebiotics, or faecalmicrobiotatransplantation, are being explored for their potential to modulateneuroinflammation and improve stroke recovery.

Neurostimulation

Neurostimulation techniques, including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), offer promising avenues for alleviating neuroinflammation in stroke. Vagus nerve stimulation (VNS), has also been found to alleviate neuroinflammation in stroke by inhibiting the activation of the NF-κBsignaling pathway and astrocyte activation[29]. By modulating neural

DOI: 10.69605/ijlbpr_13.7.2024.65

circuits and influencing neurotransmitter release, such as dopamine and serotonin, these methods may mitigate inflammatory responses post-stroke. Additionally, neurostimulation promotes neuroplasticity and may regulate glial cell activity, shifting from pro-inflammatory states to repair-promoting phenotypes. These effects potentially enhance the brain's ability to repair and restore function while reducing neuroinflammatory damage. These mechanisms highlight the potential of neurostimulation as a therapeutic approach for stroke, offering a novel strategy to mitigate neuroinflammation and promote recovery.

Neuroprotective therapy of stroke

Neuroprotective medicines aim to decrease brain damage during acute ischemic stroke by specifically targeting brain tissue to mitigate harmful molecular and cellular processes produced by reduced blood flow (Fig. 1). Over 1000 neuroprotective medicines have been assessed in preclinical stroke studies, several of which have shown encouraging outcomes in mitigating stroke damage. These preclinical research have led to the completion of around 200 clinical trials focused on neuroprotection. Regrettably, these trials have had little results. The identification of excitotoxic brain damage as the primary molecular mechanism to target is crucial for improving ischemic brain injury. Disruption of the flow of blood to the brain leads to a decrease in ATP levels, which in turn causes the neurons to become depolarized. This results in the release of the neurotransmitter glutamate, which subsequently induces an overstimulation of the ionotropic (AMPA, kainate, and NMDA) glutamatergic receptors. These events further lead to increased calcium influx and eventually lead to damage to proteins, lipids, and DNA. Regrettably, almost all of the potentially beneficial treatments aimed at addressing excitotoxic brain injury had no positive results in human studies.



Cellular and molecular target(s) of neuroprotection in acute ischemic stroke. (a) Excitotoxicity. Following oxygen and glucose deprivation, glutamate and calcium are released, which causes excitotoxic neuronal damage by overactivation of ionotropic glutamate receptors. (b) Inflammation. Membrane depolarization causes ATP depletion, resulting in failure of ionic pumps, which in turn causes cytotoxic brain edema. Inflammatory pathways, such as leukocyte infiltration, inflammatory mediators, and microglial activation, also contribute to neuronal cell death. (c) Oxidative stress. Mitochondrial dysfunction leads to reactive oxygen species and free radical generation, resulting in increased oxidative stress. (d) Apoptosis. Apoptosis is also increased in the ischemic brain because of DNA damage and mitochondrial dysfunction. Created with BioRender. Abbreviations: NO, nitric oxide; ROS, reactive oxygen species

CONCLUSION

The current investigation into innovative treatment strategies for reducing neuroinflammation in stroke holds significant promise, offering a potential breakthrough in how this debilitating condition is managed. Neuroinflammation plays a critical role in the pathogenesis of stroke, exacerbating damage and impeding recovery. Addressing this inflammation effectively could mitigate the severe outcomes often associated with stroke. Various approaches are being explored to target and alleviate neuroinflammation. Among them, cell-based treatments have garnered considerable attention. These treatments involve the use of stem cells or other specialized cells to not only

DOI: 10.69605/ijlbpr_13.7.2024.65

promote tissue repair but also to exert anti-inflammatory effects. Stem cells, such as mesenchymal stem cells (MSCs), can differentiate into a range of cell types, providing a multifaceted approach to repair damaged brain tissue and modulate the immune response. The potential for these cells to secrete anti-inflammatory cytokines further enhances their therapeutic value, positioning them as a key player in stroke treatment.

Nanoparticle-based drug delivery systems represent another promising avenue. These systems enable the targeted and controlled release of therapeutic agents, ensuring that drugs reach the affected areas in optimal concentrations while minimizing systemic side effects. The ability of nanoparticles to cross the blood-brain barrier is particularly advantageous in treating neurological conditions. By delivering drugs directly to the site of injury, nanoparticles can improve the efficacy of treatment and reduce the risk of adverse effects, making them a powerful tool in the fight against neuroinflammation. Gene therapy is also being actively investigated for its potential to regulate the immune response and reduce inflammation. This approach involves modifying genes to produce therapeutic proteins that can address specific genetic factors contributing to neuroinflammation and stroke. Techniques such as CRISPR-Cas9 allow for precise gene editing, offering the possibility of correcting underlying genetic defects and promoting neuronal recovery. The ability to tailor gene therapy to individual patients based on their genetic profile could revolutionize stroke treatment, providing personalized and highly effective interventions. Immunomodulatory drugs are designed to modulate the immune system, preventing excessive inflammation and promoting a balanced immune response. These drugs can inhibit pro-inflammatory pathways and enhance anti-inflammatory mechanisms, reducing the overall inflammatory burden on the brain. Monoclonal antibodies and small molecules are among the agents being explored for their potential to fine-tune the immune response in stroke patients, offering a targeted approach to managing neuroinflammation.

Natural substances, such as polyphenols and omega-3 fatty acids, also hold promise in the treatment of neuroinflammation. Polyphenols, found in foods like berries and green tea, have demonstrated the ability to reduce oxidative stress and inflammation. Omega-3 fatty acids, commonly sourced from fish oil, are known for their anti-inflammatory properties and can improve neuronal function. These natural compounds offer a complementary approach to conventional treatments, potentially enhancing their efficacy and providing additional therapeutic benefits. To successfully transition these innovative treatments from experimental stages to practical use, ongoing progress in these fields, backed by rigorous clinical studies, is essential. Robust clinical trials will help establish the safety, efficacy, and optimal delivery methods for these therapies. Collaboration between researchers, clinicians, and industry partners will also be crucial in overcoming regulatory and manufacturing challenges. The continued investment in research and development will be pivotal in transforming these promising strategies into viable treatments. By addressing the underlying inflammatory processes in stroke, these therapies have the potential to significantly enhance recovery, reduce long-term disability, and improve the quality of life for stroke survivors. As these innovative approaches advance through clinical testing and into clinical practice, they offer hope for a future where the devastating impact of stroke can be substantially mitigated, leading to better outcomes for patients worldwide.

REFERENCES

1. Benjamin EJ et al. (2018) Heart Disease and Stroke Statistics-2018 Update: a report from the American Heart Association. *Circulation* 137, e67–e492
2. Brzica H et al. (2017) Role of transporters in central nervous system drug delivery and blood–brain barrier protection: relevance to treatment of stroke. *J. Cent. Nerv. Syst. Dis*. 9, 1179573517693802.
3. Onwuekwe I et al. (2012) Ischemic stroke and neuroprotection. *Ann. Med. Health Sci. Res*. 2, 186–190
4. Thompson BJ and Ronaldson PT (2014) Drug delivery to the ischemic brain. *Adv. Pharmacol*. 71, 165–202
5. Sifat AE et al. (2017) Blood-brain barrier protection as a therapeutic strategy for acute ischemic stroke. *AAPS J*. 19, 957–972
6. Chamorro Á et al. (2016) Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. *Lancet Neurol*. 15, 869–881
7. Tsuji K et al. (2005) Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. *Stroke* 36, 1954–1959
8. Xin, H., Li, Y., Cui, Y., Yang, J. J., Zhang, Z. G., &Chopp, M. (2013). "Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats." *Journal of Cerebral Blood Flow & Metabolism*, 33(11), 1711-1715.
9. Bacigaluppi, M., Russo, G. L., Peruzzotti-Jametti, L., Rossi, S., Sandrone, S., Butti, E., ... & Martino, G. (2009). "Neural stem cell transplantation induces stroke recovery by upregulating glutamate transporter GLT-1 in astrocytes." *Journal of Neuroscience*, 29(47), 14795-14802.
10. Tornero, D., Wattananit, S., Grønning Madsen, M., Koch, P., Wood, J., Tatarishvili, J., ... &Parmar, M. (2013). "Human induced pluripotent stem cell-derived cortical neurons integrate in stroke-injured cortex and improve functional recovery." *Brain*, 136(12), 3561-3577.
11. Ma, Y., Wang, J., Wang, Y., Yang, G. Y. (2017). "The biphasic function of microglia in ischemic stroke." *Progress in Neurobiology*, 157, 247-272.
12. Blanco, E., Shen, H., & Ferrari, M. (2015). "Principles of nanoparticle design for overcoming biological barriers to drug delivery." Nature Biotechnology, 33(9), 941-951.

DOI: 10.69605/ijlbpr_13.7.2024.65

13. Kim, J. Y., Kim, Y. H., Kim, S. W., &Khang, G. (2016). "PLGA nanoparticles for delivering hydrophilic drugs." Journal of Controlled Release, 263, 26-36.
14. Kim, T., Lee, N., Arifin, D. R., Shats, I., Janowski, M., Walczak, P., &Bulte, J. W. (2013). "In vivo micro-CT imaging of human mesenchymal stem cells labeled with gold-poly-l-lysine nanocomplexes." Advanced Functional Materials, 23(41), 5035-5042.
15. Modo, M., Hoehn, M., &Bulte, J. W. (2013). "Cellular MR imaging." Molecular Imaging, 12(6), 450-467.
16. Estevez, A. Y., Pritchard, S., Harper, K., Aston, J. W., Lynch, A., Lucky, J. J., ... &Zesiewicz, T. A. (2011). "Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia." Free Radical Biology and Medicine, 51(6), 1155-1163
17. Feng, X., Chen, W., & Shao, S. (2018). "Nanoscale delivery systems for siRNA-based therapeutics." *Nanoscale Research Letters*, 13, 118.
18. Wang, H., Yang, H., &Shivalila, C. S. (2013). "One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering." *Cell*, 153(4), 910-918.
19. Qiao, H., Zhang, H., Zheng, Y., Peltzer, K., & Zhang, L. (2013). "The inhibitory effects of adeno-associated virus-mediated interleukin-10 expression on lipopolysaccharide-induced inflammatory responses in astrocytes." *Neuroreport*, 24(16), 919-924.
20. Furrie, E., Macfarlane, S., Cummings, J. H., & Macfarlane, G. T. (2005). "Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response." *Gut*, 54(1), 91-98.
21. Kim, S. S., Rait, A., Kim, E., Pirollo, K. F., Nishida, M., & Chang, E. H. (2011). "A nanoparticle gene delivery system for anti-cancer therapeutics." *Progress in Molecular Biology and Translational Science*, 104, 383-421
22. Rhen, T., &Cidlowski, J. A. (2005). "Antiinflammatory action of glucocorticoids—new mechanisms for old drugs." *New England Journal of Medicine*, 353(16), 1711-1723.
23. Warner, T. D., & Mitchell, J. A. (2004). "Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?" *Proceedings of the National Academy of Sciences*, 101(34), 12511-12513.
24. McCann, S. K., &Roulston, C. L. (2013). "Targeting tumor necrosis factor alpha in the treatment of acute ischemic stroke: a translational perspective." *BioMed Research International*, 2013, 628408.
25. Shichita, T., Ito, M., Yoshimura, A. (2014). "Post-ischemic inflammation regulates neural damage and protection." *Frontiers in Cellular Neuroscience*, 8, 319.
26. Plane, J. M., Shen, Y., Pleasure, D. E., & Deng, W. (2010). "Prospects for minocycline neuroprotection." *Archives of Neurology*, 67(12), 1442-1448.
27. Vaughan, C. J., &Delanty, N. (1999). "Neuroprotective properties of statins in cerebral ischemia and stroke." *Stroke*, 30(9), 1969-1973
28. Kazuo Yamashir., Naohide Kurita., Takao Urabe., &Nobutaka Hattori (2021). "Role of the Gut Microbiota in Stroke Pathogenesis and Potential Therapeutic Implications." Ann NutrMetab (2021) 77 (Suppl. 2): 36–44
29. Matyas Jelinek., Jolana Lipkova., & Kamil Duris "Vagus nerve stimulation as immunomodulatory therapy for stroke: A comprehensive review." Experimental Neurology Volume 372, February 2024, 114628